Denali Therapeutics
DNLI
DNLI
216 hedge funds and large institutions have $4.59B invested in Denali Therapeutics in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 78 increasing their positions, 69 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
7.4% less ownership
Funds ownership: 73.91% → 66.51% (-7.4%)
25% less capital invested
Capital invested by funds: $6.13B → $4.59B (-$1.53B)
Holders
216
Holding in Top 10
5
Calls
$8.56M
Puts
$4.85M
Top Buyers
| 1 | +$46M | |
| 2 | +$31.7M | |
| 3 | +$17.1M | |
| 4 |
Renaissance Technologies
New York
|
+$15.2M |
| 5 |
Morgan Stanley
New York
|
+$13.9M |
Top Sellers
| 1 | -$541M | |
| 2 | -$47.2M | |
| 3 | -$27.1M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$23.2M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$14.8M |